26.74
0.11%
0.03
Handel nachbörslich:
26.59
-0.15
-0.56%
Schlusskurs vom Vortag:
$26.71
Offen:
$26.92
24-Stunden-Volumen:
353.41K
Relative Volume:
2.10
Marktkapitalisierung:
$1.69B
Einnahmen:
$286.00M
Nettoeinkommen (Verlust:
$305.47M
KGV:
-11.41
EPS:
-2.3434
Netto-Cashflow:
$-492.33M
1W Leistung:
-6.31%
1M Leistung:
-8.39%
6M Leistung:
-8.08%
1J Leistung:
-27.85%
Galapagos Nv Adr Stock (GLPG) Company Profile
Firmenname
Galapagos Nv Adr
Sektor
Branche
Telefon
-
Adresse
-
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
2024-08-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2024-03-28 | Herabstufung | BofA Securities | Neutral → Underperform |
2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2023-08-24 | Herabstufung | Citigroup | Buy → Neutral |
2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2023-01-23 | Hochstufung | Jefferies | Underperform → Hold |
2022-11-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2022-01-27 | Hochstufung | Citigroup | Neutral → Buy |
2021-08-19 | Herabstufung | Barclays | Overweight → Equal Weight |
2021-08-06 | Herabstufung | Deutsche Bank | Buy → Hold |
2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
2021-04-14 | Hochstufung | Barclays | Equal Weight → Overweight |
2021-02-23 | Hochstufung | BofA Securities | Underperform → Neutral |
2021-02-19 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-11-19 | Eingeleitet | Maxim Group | Buy |
2020-10-21 | Herabstufung | Goldman | Neutral → Sell |
2020-08-25 | Herabstufung | Jefferies | Buy → Hold |
2020-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2020-08-19 | Herabstufung | Barclays | Overweight → Equal Weight |
2020-08-19 | Hochstufung | Citigroup | Neutral → Buy |
2020-07-10 | Herabstufung | Stifel | Buy → Hold |
2020-03-30 | Hochstufung | Jefferies | Hold → Buy |
2020-03-18 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
2020-02-25 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2020-02-24 | Herabstufung | BofA/Merrill | Neutral → Underperform |
2020-02-20 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
2020-01-06 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-12-18 | Herabstufung | Citigroup | Buy → Neutral |
2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
2019-12-02 | Eingeleitet | BofA/Merrill | Neutral |
2019-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
2019-07-31 | Hochstufung | UBS | Neutral → Buy |
2019-07-29 | Herabstufung | Jefferies | Buy → Hold |
Alle ansehen
Galapagos Nv Adr Aktie (GLPG) Neueste Nachrichten
Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK
Galapagos receives transparency notification from EcoR1 Capital - GlobeNewswire Inc.
Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com
Navigating GLPG Stock: Galapagos NV ADR Journey - The InvestChronicle
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga
Morgan Stanley cuts Galapagos NV target to $32 from $35 - Investing.com
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Belgium stocks higher at close of trade; BEL 20 up 1.37% - Investing.com
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.90% - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.24% By Investing.com - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.32% By Investing.com - Investing.com
Galapagos NV shares poised for outperformance, says TD Cowen - Investing.com India
Galapagos NV shares poised for outperformance, says TD Cowen By Investing.com - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.79% By Investing.com - Investing.com
Belgium shares lower at close of trade; BEL 20 down 0.79% - Investing.com India
Belgium stocks higher at close of trade; BEL 20 up 1.28% By Investing.com - Investing.com
Belgium shares higher at close of trade; BEL 20 up 1.28% - Investing.com India
Belgium stocks lower at close of trade; BEL 20 down 0.40% By Investing.com - Investing.com
Belgium shares lower at close of trade; BEL 20 down 0.40% - Investing.com India
Adaptimmune and Galapagos partner on cancer therapy By Investing.com - Investing.com
Adaptimmune and Galapagos partner on cancer therapy - Investing.com India
Are Medical Stocks Lagging Galapagos (GLPG) This Year? - Yahoo Singapore News
Earnings call: Galapagos outlines strategic focus in Q1 2024 results - Investing.com
Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More - Yahoo News UK
Insight venture partners executives sell over $61 million in nCino shares By Investing.com - Investing.com
Allied Gaming & Entertainment insider buys shares worth over $456,000 By Investing.com - Investing.com
Morgan Stanley sets Galapagos stock at equalweight, $38 price target By Investing.com - Investing.com
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA - Yahoo Finance
Morgan Stanley lists biotechs with negative enterprise value, 2022 catalysts (NASDAQ:GLPG) - Seeking Alpha
Galapagos Surges On New CEO and Upgrade News - Investing.com
Galapagos: Market Values Pipeline Below $0 (NASDAQ:GLPG) - Seeking Alpha
Galapagos Begins Dosing With GLPG3970 in Psoriasis Study - Yahoo Singapore News
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs - Benzinga
The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs - Yahoo Finance
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves I - Benzinga
The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integr - Benzinga
Is Galapagos NV (GLPG) A Good Stock To Buy? - Insider Monkey
The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares - Yahoo Finance
The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes DividendAlecto - Benzinga
World’s Top-Selling Drugs: Gilead Sciences, Inc. Sovaldi Closes In On AbbVie Inc Humira - Crypto Coins Tribune
The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To DebutStaar S - Benzinga
The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOsAmarin Corp (NASDAQ:A - Benzinga
AIM tech shares that broke America - Interactive Investor
25 Stocks Moving In Friday's Pre-Market SessionAlnylam Pharmaceuticals (NASDAQ:ALNY), Aclaris Therapeu - Benzinga
Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn't Worth the Risk - InvestorPlace
Finanzdaten der Galapagos Nv Adr-Aktie (GLPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):